Palatin Technologies announces 1-for-50 reverse stock split

PRINCETON, N.J. - Palatin Technologies, Inc. (OTCQB:PTNT), a micro-cap biotech currently trading at $0.18 with a market capitalization of $8.87 million, announced today a 1-for-50 reverse stock split that will take effect today at 5:00 p.m. Eastern Daylight Time. The biopharmaceutical company’s shares are expected to begin trading on a split-adjusted basis on the OTCQB Market on Monday, August 11, 2025.

Following the split, the company’s ticker symbol will temporarily change to PTNTD for 20 trading days before reverting to PTNT. The company’s post-split CUSIP number will be 696077 601. According to InvestingPro analysis, Palatin currently shows a Weak financial health score, with the stock down over 80% year-to-date, though analysts suggest the shares may be undervalued at current levels.

According to the press release, a primary goal of the reverse split is to increase the per-share market price to meet NYSE American’s listing qualifications related to minimum share price requirements. The company’s current ratio of 0.32 and steep revenue decline of 94% over the last twelve months underscore the challenges that led to this corporate action. Get deeper insights into Palatin’s financial metrics and more exclusive analysis with InvestingPro.

Palatin stockholders approved the reverse split during the annual meeting on July 25, 2025, authorizing the company’s board to implement a ratio between 1-for-50 and 1-for-100. The board ultimately selected the 1-for-50 ratio.

As part of the split, every 50 shares of Palatin’s issued and outstanding common stock will be combined into one share. Stockholders will receive cash for any fractional shares resulting from the transaction, while the par value and other terms of the common stock will remain unchanged.

Palatin Technologies focuses on developing medicines based on molecules that modulate melanocortin receptor systems for treating diseases with unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.